1. Home
  2. MYNZ vs BGLC Comparison

MYNZ vs BGLC Comparison

Compare MYNZ & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYNZ
  • BGLC
  • Stock Information
  • Founded
  • MYNZ 2021
  • BGLC N/A
  • Country
  • MYNZ Germany
  • BGLC Malaysia
  • Employees
  • MYNZ N/A
  • BGLC 30
  • Industry
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • BGLC Medical Specialities
  • Sector
  • MYNZ Health Care
  • BGLC Health Care
  • Exchange
  • MYNZ Nasdaq
  • BGLC Nasdaq
  • Market Cap
  • MYNZ 9.8M
  • BGLC 9.1M
  • IPO Year
  • MYNZ 2021
  • BGLC N/A
  • Fundamental
  • Price
  • MYNZ $0.35
  • BGLC $0.52
  • Analyst Decision
  • MYNZ Buy
  • BGLC
  • Analyst Count
  • MYNZ 2
  • BGLC 0
  • Target Price
  • MYNZ $3.00
  • BGLC N/A
  • AVG Volume (30 Days)
  • MYNZ 1.4M
  • BGLC N/A
  • Earning Date
  • MYNZ 08-13-2024
  • BGLC N/A
  • Dividend Yield
  • MYNZ N/A
  • BGLC N/A
  • EPS Growth
  • MYNZ N/A
  • BGLC N/A
  • EPS
  • MYNZ N/A
  • BGLC N/A
  • Revenue
  • MYNZ $895,479.00
  • BGLC N/A
  • Revenue This Year
  • MYNZ $67.40
  • BGLC N/A
  • Revenue Next Year
  • MYNZ $191.13
  • BGLC N/A
  • P/E Ratio
  • MYNZ N/A
  • BGLC N/A
  • Revenue Growth
  • MYNZ 69.00
  • BGLC N/A
  • 52 Week Low
  • MYNZ $0.32
  • BGLC N/A
  • 52 Week High
  • MYNZ $4.71
  • BGLC N/A
  • Technical
  • Relative Strength Index (RSI)
  • MYNZ 37.39
  • BGLC 54.78
  • Support Level
  • MYNZ $0.39
  • BGLC $0.46
  • Resistance Level
  • MYNZ $0.46
  • BGLC $0.59
  • Average True Range (ATR)
  • MYNZ 0.07
  • BGLC 0.04
  • MACD
  • MYNZ 0.01
  • BGLC 0.01
  • Stochastic Oscillator
  • MYNZ 13.88
  • BGLC 45.41

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Share on Social Networks: